annb0t
Top 20
Market forces rained on the parade of Mayne Pharma Group Limited (ASX:MYX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) estimates were cut sharply as the analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.
Following the downgrade, the most recent consensus for Mayne Pharma Group from its five analysts is for revenues of AU$409m in 2022 which, if met, would be a...
>>> Read more: Mayne Pharma Group Limited (ASX:MYX) Analysts Just Slashed This Year's Estimates
Following the downgrade, the most recent consensus for Mayne Pharma Group from its five analysts is for revenues of AU$409m in 2022 which, if met, would be a...
>>> Read more: Mayne Pharma Group Limited (ASX:MYX) Analysts Just Slashed This Year's Estimates
